Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma

NCT01919086 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma (MM)

Interventions

DRUG: Bortezomib
DRUG: Dexamethasone
DRUG: Lenalidomide

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]